ArticleACS medicinal chemistry letters2016
Identification of
Article in ACS medicinal chemistry letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Imidazo[1,2‑ACS omega · 2026Review
- C-C Bond Formation via Direct Functionalization of Indolizines with a Bichromophoric Ruthenium Photocatalyst.ACS organic & inorganic Au · 2026Article
- Imidazo[1,2‑ACS omega · 2026Review
- Targeting opportunities presented by the pyrimidine biosynthesis pathway in Mycobacterium tuberculosis: a brief review.Biochemical Society transactions · 2026Review
- Recent developments of imidazo[1,2-RSC medicinal chemistry · 2023Review
- Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022.International journal of molecular sciences · 2022Review
- Design, synthesis and anti-mycobacterial evaluation of imidazo[1,2-RSC medicinal chemistry · 2022Article
- Synthesis, study of antileishmanial and antitrypanosomal activity of imidazo pyridine fused triazole analogues.RSC advances · 2020Article
- Molecule Property Analyses of Active Compounds forJournal of medicinal chemistry · 2020Review
- Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?Frontiers in cellular and infection microbiology · 2020Review
- Identification ofACS medicinal chemistry letters · 2018Article
- Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds.ChemMedChem · 2017Article
- Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds.Pharmaceuticals (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of imidazo[1,2-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.